Patryk Kambakamba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Patryk Kambakamba has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Pierre-Alain Clavien
Department of Surgery and Transplantation, University of Zurich, Zurich, Switzerland
3 shared publications - Philipp Kron
University Clinic for General, Visceral and Transplantation Surgery, University Hospital Tübingen, Tübingen, Germany
2 shared publications Andrea Wirsching
Department of Surgery and Transplantation, University Hospital Zurich, Switzerland
1 shared publication- Bostjan Humar
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zürich, Zürich, Switzerland
1 shared publication C. Liliana
Department of Surgery Swiss HPB and Transplant Surgery, University Hospital Zurich, Switzerland
1 shared publicationChristian Oberkofler
Department of Surgery and Transplantation, University Hospital Zurich, Switzerland
1 shared publication
Latest Publications
- Open Access
- 11 July 2020
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 107 (9) , e334-e335
The peer review at high risk from COVID-19 – are we socially distancing from scientific quality control?
- 11 July 2020
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 107 (9) , e334-e335
Open AccessThe peer review at high risk from COVID-19 – are we socially distancing from scientific quality control?
- 1 March 2020
- Published by Elsevier in Journal of Hepatology
- Vol. 72 (3) , 498-505
Perioperative omega-3 fatty acids fail to confer protection in liver surgery: Results of a multicentric, double-blind, randomized controlled trial
- 1 March 2020
- Published by Elsevier in Journal of Hepatology
- Vol. 72 (3) , 498-505
Perioperative omega-3 fatty acids fail to confer protection in liver surgery: Results of a multicentric, double-blind, randomized controlled trial
- Open Access
- 1 August 2017
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 266 (2) , 324-332
Omega-3 Fatty Acids Protect Fatty and Lean Mouse Livers After Major Hepatectomy
The aim of this study was to assess the effect of Ω3 fatty acids (Ω3FA) on fatty and lean liver in hepatic surgery. The global spread of energy-dense diets has led to an endemic rise in fatty liver disease and obesity. Besides metabolic pathologies, steatosis enhances hepatic sensitivity to ischemia reperfusion (I/R) and impedes liver regeneration (LR). Steatosis limits the application of liver surgery, still the main curative option for liver cancer. Ω3FA are known to reverse steatosis, but how these lipids affect key factors defining surgical outcomes—that is, I/R, LR, and liver malignancy—is less clear. We established a standardized mouse model of high fat diet (HFD)-induced steatosis followed by Ω3FA treatment and the subsequent assessment of Ω3FA effects on I/R, LR, and liver malignancy (n = 5/group), the latter through a syngeneic metastasis approach. Fatty liver outcomes were compared with lean liver to assess steatosis-independent effects. Nonparametric statistics were applied. Ω3FA reversed HFD-induced steatosis and markedly protected against I/R, improved LR, and prolonged survival of tumor-laden mice. Remarkably, these beneficial effects were also observed in lean liver, albeit at a smaller scale. Notably, mice with metastases in fatty versus lean livers were associated with improved survival. Ω3FA revealed multiple beneficial effects in fatty and lean livers in mice. The improvements in I/R injury, regenerative capacity, and oncological outcomes await confirmatory studies in humans.
- 1 August 2017
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 266 (2) , 324-332
Open AccessOmega-3 Fatty Acids Protect Fatty and Lean Mouse Livers After Major Hepatectomy
The aim of this study was to assess the effect of Ω3 fatty acids (Ω3FA) on fatty and lean liver in hepatic surgery. The global spread of energy-dense diets has led to an endemic rise in fatty liver disease and obesity. Besides metabolic pathologies, steatosis enhances hepatic sensitivity to ischemia reperfusion (I/R) and impedes liver regeneration (LR). Steatosis limits the application of liver surgery, still the main curative option for liver cancer. Ω3FA are known to reverse steatosis, but how these lipids affect key factors defining surgical outcomes—that is, I/R, LR, and liver malignancy—is less clear. We established a standardized mouse model of high fat diet (HFD)-induced steatosis followed by Ω3FA treatment and the subsequent assessment of Ω3FA effects on I/R, LR, and liver malignancy (n = 5/group), the latter through a syngeneic metastasis approach. Fatty liver outcomes were compared with lean liver to assess steatosis-independent effects. Nonparametric statistics were applied. Ω3FA reversed HFD-induced steatosis and markedly protected against I/R, improved LR, and prolonged survival of tumor-laden mice. Remarkably, these beneficial effects were also observed in lean liver, albeit at a smaller scale. Notably, mice with metastases in fatty versus lean livers were associated with improved survival. Ω3FA revealed multiple beneficial effects in fatty and lean livers in mice. The improvements in I/R injury, regenerative capacity, and oncological outcomes await confirmatory studies in humans.
- 1 October 2014
- Published by Elsevier in The American Journal of Surgery
- Vol. 208 (4) , 563-570
Perihilar cholangiocarcinoma: paradigms of surgical management
- 1 October 2014
- Published by Elsevier in The American Journal of Surgery
- Vol. 208 (4) , 563-570
Perihilar cholangiocarcinoma: paradigms of surgical management